NCT03924193View on ClinicalTrials.gov

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions
Binge-Eating DisorderObesity
Interventions
DRUG

Lisdexamfetamine Dimesylate

Participants randomly assigned to this arm will receive 12 weeks of LDX medication.

BEHAVIORAL

Cognitive-Behavioral Therapy

Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy

OTHER

Combination LDX and Cognitive-Behavioral Therapy

Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy

Trial Locations (1)

06510

Yale Department of Psychiatry, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT03924193 - Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment | Biotech Hunter | Biotech Hunter